Literature DB >> 9770530

Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.

X J Lou1, N W Boonmark, F T Horrigan, J L Degen, R M Lawn.   

Abstract

To test directly whether fibrin(ogen) is a key binding site for apolipoprotein(a) [apo(a)] in vessel walls, apo(a) transgenic mice and fibrinogen knockout mice were crossed to generate fibrin(ogen)-deficient apo(a) transgenic mice and control mice. In the vessel wall of apo(a) transgenic mice, fibrin(ogen) deposition was found to be essentially colocalized with focal apo(a) deposition and fatty-streak type atherosclerotic lesions. Fibrinogen deficiency in apo(a) transgenic mice decreased the average accumulation of apo(a) in vessel walls by 78% and the average lesion (fatty streak type) development by 81%. Fibrinogen deficiency in wild-type mice did not significantly reduce lesion development. Our results suggest that fibrin(ogen) provides one of the major sites to which apo(a) binds to the vessel wall and participates in the generation of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770530      PMCID: PMC22875          DOI: 10.1073/pnas.95.21.12591

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.

Authors:  J M Edelberg; M Gonzalez-Gronow; S V Pizzo
Journal:  Thromb Res       Date:  1990-01-01       Impact factor: 3.944

Review 2.  Lp(a): an interloper into the fibrinolytic system?

Authors:  L A Miles; E F Plow
Journal:  Thromb Haemost       Date:  1990-06-28       Impact factor: 5.249

Review 3.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site.

Authors:  M Gonzalez-Gronow; J M Edelberg; S V Pizzo
Journal:  Biochemistry       Date:  1989-03-21       Impact factor: 3.162

5.  Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice.

Authors:  B Paigen; B Y Ishida; J Verstuyft; R B Winters; D Albee
Journal:  Arteriosclerosis       Date:  1990 Mar-Apr

6.  Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; J L Degen
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 7.  The mysteries of lipoprotein(a).

Authors:  G Utermann
Journal:  Science       Date:  1989-11-17       Impact factor: 47.728

8.  Lipoprotein(a), fibrin binding, and plasminogen activation.

Authors:  J Loscalzo; M Weinfeld; G M Fless; A M Scanu
Journal:  Arteriosclerosis       Date:  1990 Mar-Apr

9.  Quantitative assessment of atherosclerotic lesions in mice.

Authors:  B Paigen; A Morrow; P A Holmes; D Mitchell; R A Williams
Journal:  Atherosclerosis       Date:  1987-12       Impact factor: 5.162

10.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.

Authors:  K A Hajjar; D Gavish; J L Breslow; R L Nachman
Journal:  Nature       Date:  1989-05-25       Impact factor: 49.962

View more
  10 in total

Review 1.  Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors:  Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

Review 2.  Genetic modifiers of atherosclerosis in mice.

Authors:  J W Knowles; N Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

3.  Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.

Authors:  Simon Kraler; Mark C Blaser; Elena Aikawa; Giovanni G Camici; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2022-02-12       Impact factor: 29.983

4.  Fibulin-1 and fibrinogen in human atherosclerotic lesions.

Authors:  W Scott Argraves; Asashi Tanaka; Elizabeth P Smith; Waleed O Twal; Kelley M Argraves; Daping Fan; Christian C Haudenschild
Journal:  Histochem Cell Biol       Date:  2009-08-20       Impact factor: 4.304

Review 5.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

Review 6.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

7.  Fibrin-mediated protection against infection-stimulated immunopathology.

Authors:  Lawrence L Johnson; Kiera N Berggren; Frank M Szaba; Wangxue Chen; Stephen T Smiley
Journal:  J Exp Med       Date:  2003-03-10       Impact factor: 14.307

8.  Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis.

Authors:  R Salvi; V Péclat; A So; N Busso
Journal:  Arthritis Res       Date:  2000-09-20

9.  Blood coagulation and the risk of atherothrombosis: a complex relationship.

Authors:  Henri Mh Spronk; Danielle van der Voort; Hugo Ten Cate
Journal:  Thromb J       Date:  2004-12-01

Review 10.  Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.

Authors:  Hugo Ten Cate; Tomasz J Guzik; John Eikelboom; Henri M H Spronk
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.